U.S. Markets open in 2 hrs 19 mins

Sanofi (SNY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
49.16-0.15 (-0.30%)
At close: 4:02PM EDT

49.40 0.24 (0.49%)
Pre-Market: 6:51AM EDT

People also watch
Interactive chart
Previous Close49.31
Bid49.25 x 100
Ask49.50 x 1000
Day's Range49.11 - 49.45
52 Week Range36.81 - 50.24
Avg. Volume1,656,912
Market Cap117.67B
PE Ratio (TTM)24.82
Earnings DateN/A
Dividend & Yield1.58 (3.20%)
Ex-Dividend Date2017-05-11
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals1 hour ago

    ​Sanofi Genzyme takes on world’s top-selling drugs with new approval

    With Monday’s announcement that U.S. regulators have approved a drug for rheumatoid arthritis developed by Sanofi Genzyme and Regeneron Pharmaceuticals, the two drugmakers revealed a tried-and-true strategy to take on the world’s number one and number three best-selling drugs, which also happen to be for that same disease: give it a lower price. Cambridge-based Sanofi Genzyme (SNY) and Tarrytown, N.Y.-based Regeneron (REGN) will market their new drug, which has the generic name of sarilumab, under the name of Kevzara. Rheumatoid arthritis affects about 1.3 million Americans, mostly women, and Kevzara is approved for those with moderate to severe forms of the disease that aren’t well treated by other drugs.

  • Reuters13 hours ago

    Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval

    The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc and Sanofi SA's biotech drug for adults with moderate to severe rheumatoid arthritis, the two companies said on Monday. The drug, sarilumab, which will be sold under the brand name Kevzara, will carry a list price of $39,000 per year for the 200 milligram and 150 mg doses, which the companies said was about 30 percent lower than the list price for the two most widely used rival medicines in the highly competitive space. The approval marks a second major regulatory victory for the two companies in recent weeks after their potential blockbuster treatment for severe atopic dermatitis, Dupixent, won U.S. approval in late March.

  • Sanofi Wins Favorable CHMP Opinion for Biosimilar Humalog
    Zacks15 hours ago

    Sanofi Wins Favorable CHMP Opinion for Biosimilar Humalog

    Sanofi (SNY) recently announced that the CHMP has given a positive opinion, recommending marketing approval to a biosimilar version of Humalog (insulin lispro).